Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: An open label trial

Journal of Hepatology

Volumn 50, Issue 3, 2009, Pages 584-591

  Sharma, Praveen ^a,b   Kumar, Ashish ^a,b   Sharma, Barjesh Chander ^a   Sarin, Shiv Kumar ^a,b  

^a UNIVERSITY OF DELHI   (India)

^b INSTITUTE OF LIVER AND BILIARY SCIENCES   (India)

Author keywords

Alcohol; Alcoholic liver disease; Delta bilirubin at day 7; Discriminant function; Hepatic encephalopathy; Tumor necrosis factor (TNF)

Indexed keywords

BILIRUBIN; C REACTIVE PROTEIN; CEFTRIAXONE; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; BILIRUBIN BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CLINICAL TRIAL; DEATH; DISEASE SEVERITY; DRUG HALF LIFE; FEMALE; HEPATIC ENCEPHALOPATHY; HOSPITAL ADMISSION; HUMAN; MALE; MILIARY TUBERCULOSIS; MONOTHERAPY; MORTALITY; NEUTROPHIL COUNT; OPEN STUDY; OVERALL SURVIVAL; PNEUMONIA; PRIORITY JOURNAL; SCORING SYSTEM; SEPSIS; SINGLE DRUG DOSE;

ADULT; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; BACTERIAL INFECTIONS; BILIRUBIN; BLOOD PROTEINS; DISEASE PROGRESSION; HEPATITIS, ALCOHOLIC; HUMANS; INTERNATIONAL NORMALIZED RATIO; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PATIENT SELECTION; SERUM ALBUMIN; SURVIVAL ANALYSIS; SURVIVORS; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 59549100657     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.10.024     Document Type: Article

References (26)

1. Ramond M.J., Poynard T., Rueff B., Mathurin P., Théodore C., Chaput J.C., et al. A randomized trial of prednisolone in patients with severe alcoholic hepatitis. N Engl J Med 326 (1992) 507-512
2. Hardison W.G., and Lee F.I. Prognosis in acute liver disease of the alcoholic patient. N Engl J Med 275 (1966) 61-66
3. Lopez-Talavera J.C., Merrill W.W., and Groszmann R.J. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 108 (1995) 761-767
4. Lopez-Talavera J.C., Cadelina G., Olchowski J., Merrill W., and Groszmann R.J. Thalidomide inhibits tumor necrosis factor alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology 23 (1996) 1616-1621
5. McClain C.J., Barve S., Deaciuc I., Kugelmas M., and Hill D. Cytokines in alcoholic liver disease. Semin Liver Dis 19 (1999) 205-219
6. Bird G.L., Sheron N., Goka A.K., Alexander G.J., and Williams R.S. Increased plasma tumor necrosis factor in severe alcoholic hepatitis. Ann Intern Med 112 (1990) 917-920
7. Alvarez M.A., Cabré E., Lorenzo-Zúñiga V., Montoliu S., Planas R., and Gassull M.A. Combining steroids with enteral nutrition: a better therapeutic strategy for severe alcoholic hepatitis? Results of a pilot study. Eur J Gastroenterol Hepatol 16 (2004) 1375-1380
8. Reynolds T.B. Corticosteroid therapy of alcoholic hepatitis: how many studies will it take?. Hepatology 12 (1990) 619-621
9. Imperiale T.F., and McCullough A.J. Do corticosteroids reduce mortality from alcoholic hepatitis? A meta-analysis of the randomized trials. Ann Intern Med 113 (1990) 299-307
10. Mathurin P., Mendenhall C.L., Carithers Jr. R.L., Ramond M.J., Maddrey W.C., Garstide P., et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis (AH): individual data analysis of the last three randomized placebo controlled double blind trials of corticosteroids in severe AH. J Hepatol 36 (2002) 480-487
11. Taïeb J., Mathurin P., Elbim C., Cluzel P., Arce-Vicioso M., Bernard B., et al. Blood neutrophil functions and cytokine release in severe alcoholic hepatitis: effect of corticosteroids. J Hepatol 32 (2000) 579-586
12. Tilg H., Jalan R., Kaser A., Davies N.A., Offner F.A., Hodges S.J., et al. Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. J Hepatol 38 (2003) 419-425
13. Mookerjee R.P., Sen S., Davies N.A., Hodges S.J., Williams R., and Jalan R. Tumour necrosis factor alpha is an important mediator of portal and systemic haemodynamic derangements in alcoholic hepatitis. Gut 52 (2003) 1182-1187
14. Maini R., St Clair E.W., Breedveld F., Furst D., Kalden J., Weisman M., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 354 (1999) 1932-1939
15. Present D.H., Rutgeerts P., Targan S., Hanauer S.B., Mayer L., van Hogezand R.A., et al. Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med 340 (1999) 1398-1405
16. Naveau S., Chollet-Martin S., Dharancy S., Mathurin P., Jouet P., Piquet M.A., et al. Foie-Alcool group of the Association Française pour l'Etude du Foie. A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis. Hepatology 39 (2004) 1390-1397
17. Louvet A., Naveau S., Abdelnour M., Ramond M.J., Diaz E., Fartoux L., et al. The Lille model: a new tool for therapeutic strategy in patients with severe alcoholic hepatitis treated with steroids. Hepatology 45 (2007) 1348-1354
18. Spahr L., Rubbia-Brandt L., Pugin J., Giostra E., Frossard J.L., Borisch B., et al. Rapid changes in alcoholic hepatitis histology under steroids: correlation with soluble intercellular adhesion molecule-1 in hepatic venous blood. J Hepatol 35 (2001) 582-589
19. Spahr L., Rubbia-Brandt L., Frossard J.L., Giostra E., Rougemont A.L., Pugin J., et al. Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study. J Hepatol 37 (2002) 448-455
20. Rongey C., and Kaplowitz N. Current concepts and controversies in the treatment of alcoholic hepatitis. World J Gastroenterol 12 (2006) 6909-6921
21. Mookerjee R.P., Tilg H., Williams R., and Jalan R. Infliximab and alcoholic hepatitis. Hepatology 40 (2004) 499-500
22. Boetticher N.C., Peine C.J., Kwo P., Abrams G.A., Patel T., Aqel B., et al. A randomized, double-blinded, placebo-controlled multi-center trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology 135 (2008) 1953-1960
23. Hanck C., Rossol S., Böcker U., Tokus M., and Singer M.V. Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 33 (1998) 606-608
24. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
25. Theis V.S., and Rhodes J.M. Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease. Aliment Pharmacol Ther 27 (2008) 19-30
26. Mathurin P., Abdelnour M., Ramond M.J., Carbonell N., Fartoux L., Serfaty L., et al. Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone. Hepatology 38 (2003) 1363-1369